Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Médica Sur, S.A.B. de C.V. (MEDICAB.MX)
Mexico City, DF, MX
Médica Sur, S.A.B. de C.V. functions as a leading healthcare provider within Mexico. The institution furnishes a comprehensive array of medical and surgical treatments, including intricate procedures such as bypass and gastric banding, cholecystectomy, inguinal hernia repair, liposculpture, breast augmentation, stereotactic radiosurgery, hip arthroplasty, knee and shoulder arthroscopy, spinal operations, lithiasis removal, and various prostate interventions, notably radical prostatectomy. Beyond these surgical offerings, Médica Sur also extends its services to include advanced radiotherapy, diagnostic imaging, comprehensive health check-ups, and medical insurance solutions. Established in 1966, this entity is headquartered in Mexico City and operates as a subsidiary of Neuco, SA de CV.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -0.82% | -2.42% | +7.08% | +0.83% | +35.96% | +54.73% | +83.33% | +35.96% | +2,925.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+8.8% Q4'25: +13.9% (vs Q2'24)
-
EPS growth Medical - Care Facilities: +19.2%-100.0% Q4'25: -100.0% (vs Q2'24)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+13.6% Q4'25: +13.0% (vs Q2'24)
-
EBIT margin Medical - Care Facilities: +11.3%+19.0% ★ Q4'25: +19.8% (vs Q2'24)
-
ROIC Medical - Care Facilities: +6.8%+30.8% ★ Q4'25: +31.4% (vs Q2'24)
-
Share dilution Medical - Care Facilities: +0.0%+0.7% Q4'25: +3.4% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×0.91× ★ Q4'25: 0.87× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
4.13B
est: 4.02B (+2.6%)
|
4.40B
est: 4.40B (0.0%)
|
4.79B
est: 4.79B (0.0%)
|
4.79B
4.79B – 4.79B
+0.0% YoY
|
5.12B
5.12B – 5.12B
+7.0% YoY
|
5.44B
5.44B – 5.44B
+6.1% YoY
|
5.77B
5.77B – 5.77B
+6.1% YoY
|
6.13B
6.13B – 6.13B
+6.2% YoY
|
| EBITDA |
995.50M
est: 937.18M (+6.2%)
|
863.90M
est: 1.05B (-17.4%)
|
1.11B
est: 1.14B (-2.6%)
|
1.14B
1.14B – 1.14B
+0.0% YoY
|
1.22B
1.22B – 1.22B
+7.0% YoY
|
1.29B
1.29B – 1.29B
+6.1% YoY
|
1.37B
1.37B – 1.37B
+6.1% YoY
|
1.46B
1.46B – 1.46B
+6.2% YoY
|
| EBIT |
816.89M
est: 736.89M (+10.9%)
|
669.73M
est: 854.13M (-21.6%)
|
907.83M
est: 929.01M (-2.3%)
|
929.40M
929.40M – 929.40M
+0.0% YoY
|
993.99M
993.99M – 993.99M
+7.0% YoY
|
1.05B
1.05B – 1.05B
+6.1% YoY
|
1.12B
1.12B – 1.12B
+6.1% YoY
|
1.19B
1.19B – 1.19B
+6.2% YoY
|
| Net Income |
634.98M
est: 414.28M (+53.3%)
|
461.51M
est: 453.81M (+1.7%)
|
540.25M
est: 491.63M (+9.9%)
|
537.01M
537.01M – 537.01M
+9.2% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| SGA |
868.59M
est: 528.69M (+64.3%)
|
857.09M
est: 694.23M (+23.5%)
|
935.69M
est: 755.10M (+23.9%)
|
755.41M
755.41M – 755.41M
+0.0% YoY
|
807.92M
807.92M – 807.92M
+7.0% YoY
|
857.43M
857.43M – 857.43M
+6.1% YoY
|
909.93M
909.93M – 909.93M
+6.1% YoY
|
965.90M
965.90M – 965.90M
+6.2% YoY
|
| EPS |
5.90
est: 3.86 (+52.8%)
|
4.30
est: 4.20 (+2.4%)
|
5.00
est: 4.55 (+9.9%)
|
4.97
4.97 – 4.97
+9.2% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 679.05 | 0.44% |
| 2 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 339.12 | 0.56% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 339.09 | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arely Gutierrez | Deputy Director of Financing & Investor Relations | — | — |
| Concepcion Guadalupe Arriaga Ruiloba | Director of Internal Communications Events | — | female |
| Jose Manue Correa Rovelo | Director of Operations & Director | — | — |
| Juan Antonio Chavez Nieves | Director of Human Resources | — | — |
| Juan Francisco Ahedo Rozada | Director of Finance & Administration | — | — |
| Martha Helena Ramos Ostos | Executive Director and Director of the Center for Clinical Diagnosis & Imaging | — | — |
| Moises Francisco Jose Ramos Gonzalez | Secretary & Legal Director | — | — |
| Octavio Gonzalez Chon | Director General & Director | — | — |
| Salvador Oscar Rivero Boschert | Executive Director | — | male |
| Sandra Maria Del Carmen Garcia Lopez | Director of Medicine & Hospitalization | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MEDICAB.MX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
